Salivary Interactions With Chemosensations

Purdue University

Status: Terminated

Conditions: Diet, Food Choice, Taste

Treatments: Other: Linoleic acid; Other: Capsaicin solution; Other: Capsaicin control; Other: Epigallocatechin gallate; Other: Linoleic acid control; Other: Epigallocatechin gallate control

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT03883880

082-011

Details and patient eligibility

About

A counterbalanced, crossover design will be used to evaluate whether exposure to flavors vs. a control over time alters the perception of the flavor by changing an individual's salivary protein profile. Participants will complete 3 acute tasting protocols (baseline, after intervention 1, after intervention 2). The interventions will be with the flavor (epigallocatechin gallate, linolenic acid, capsaicin) or a control, in counterbalanced order, and will involve swishing and swallowing a solution of that sample 5 times per day for two weeks. Each of these flavors will be a separate sub-study.

Full description

This study is designed to test the relationship between salivary proteins, flavor sensation, and flavor exposure. For this study, we will test the bitterness/astringency of epigallocatechin gallate (EGCG, a polyphenol), the oleogustus (fatty acid taste) of linolenic acid, and the spiciness of capsaicin in conjunction with the concentration of specific salivary proteins (initially: salivary proline rich proteins for EGCG intervention, lipocalin-1 for the other two, but other proteins may be identified in the post-hoc analysis of the salivary proteome). We will test whether higher expression of these specific salivary proteins correlates with lower intensity of these flavors. We will further attempt to confirm the role of these salivary proteins using food-sourced functional analogs for these proteins. We would expect the food-sourced protein to have the same effect on flavor as the salivary protein if our hypotheses about salivary proteins' influence on flavor are correct. Finally, we will also use denatured versions of the food-sourced proteins to again confirm that effects are due to the function of these proteins binding the flavor.

Additionally, we will repeatedly expose individuals to the flavors by having them rinse and swallow solutions of the flavor compounds multiple times per day for two weeks. We will then re-evaluate the sensory ratings and salivary protein profiles. Two weeks of rinsing and swallowing a control solution will be used as a control during this intervention (for each of the flavors of interest).

To collect saliva and establish bitterness/astringency perception, we will use an acute tasting protocol. Participants will rinse with water, then taste and swallow, then taste and expectorate a solution of the flavor of interest. Saliva will be frozen for later proteomic analysis. Next participants will taste solutions of: flavor, flavor with food analog, the flavor with denatured food analog, water, water with the food analog, and water with denatured food analog. The participants will rank these solutions in order from least intense to most intense for the flavor quality of interest (bitterness/astringency for EGCG). After this, participants will taste all 6 samples again, and rate each individually for the intensity of the bitterness/astringency. After a short wait, this tasting and intensity rating will be repeated. All tastings will be done in counterbalanced order, and solutions will be labeled with randomized 3-digit codes.

This acute tasting protocol will be done: at baseline, after 2 weeks on one intervention (repeated tasting of flavor or control), after 2 weeks on the other intervention.

Enrollment: 32 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Agree to maintain current diet throughout intervention
• Agree to inform us if medication use changes during study.
• Willing and able to taste and consume samples, as well as take pictures to document use of the flavor during intervention.

Exclusion criteria

• Known issues with salivation, taste, or smell
• Taking medications other than birth control
• User of tobacco products or electronic cigarettes within the last 30 days

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

32 participants in 3 patient groups

Epigallocatechin gallate

Experimental group

Description:

Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.

Treatment:

Other: Epigallocatechin gallate

Other: Epigallocatechin gallate control

Linoleic acid

Experimental group

Description:

Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.

Treatment:

Other: Linoleic acid control

Other: Linoleic acid

Capsaicin

Experimental group

Description:

Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.

Treatment:

Other: Capsaicin control

Other: Capsaicin solution